



PATENT

1639

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Docket No.: POUSTKA-2

In re Application of:)
ANNEMARIE POUSTKA et al.)
Serial No.: 09/880,688) Examiner: J.D. Epperson
Filed: June 13, 2001) Group Art Unit: 1639
For: METHOD AND DEVICES FOR APPLYING)
SUBSTANCES TO A SUPPORT,)
ESPECIALLY MONOMERS FOR THE)
COMBINATORIAL SYNTHESIS OF)
MOLECULE LIBRARIES)

RECEIVED
JAN 30 2004
TECH CENTER 600/2004

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

U.S. Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on <u>January 20, 2004</u> .	
(Date)	
URSULA B. DAY	
(Name of Registered Representative)	
	<u>Jan. 20, 2004</u>
Signature	Date of Signature


SIR:

This communication is in response to the Official Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated October September 24, 2003, having a shortened period for response terminating October 24, 2003.

01/29/2004 NOLAND 00000006 060502 09880680
01 FC:2253 475.00 DA

DISK TO STIC

DATE:



The Commissioner is hereby petitioned to extend the period for response to above-referenced Official Action by THREE months until January 26, 2004.

- [X] Accompanying this amendment is the appropriate fee of \$475.00 pursuant to 37 C.F.R. §1.17(c) and 37 C.F.R. §1.136(a).
- [X] The Commissioner is hereby also authorized to charge any fees which may be required during the pendency of this application, including any patent application processing fees under 37 C.F.R. 1.17, and any filing fees under 37 C.F.R. 1.16, including presentation of extra claims, or credit any overpayment to Deposit Account No: 06-0502.

Please amend this application as follows:

IN THE SPECIFICATION:

Amend the specification with the sequence listing provided herewith in CRF and paper form.